Wednesday, May 21, 2025 | 01:31 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Covid-19: Bharat Biotech's nasal vaccine gets govt nod as booster shot

The approval for the vaccine comes amid a spurt in Covid cases in China and some other countries

Nasal spray market heats up as Covid-19 curbs ease, people return to work
Premium

Representative Image

BS Web Team New Delhi
The health ministry on Friday approved Bharat Biotech's intranasal Covid-19 vaccine for inclusion in the vaccination programme as a booster dose for those above 18 years of age. The needle-free vaccine will be available at private centres. It will be introduced on the Co-WIN platform on Friday evening.

The nasal vaccine -- BBV154 -- received approval from the Drugs Controller General of India in November for restricted use in an emergency for those above 18 as a heterologous booster dose.

This will be India's first such needleless jab. As of now, Bharat Biotech's Covaxin, Serum Institute's Covishield and Covovax, Russian

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in